GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BerGenBio ASA (OSTO:BGBIOO) » Definitions » LT-Debt-to-Total-Asset

BerGenBio ASA (OSTO:BGBIOO) LT-Debt-to-Total-Asset : 0.00 (As of Dec. 2023)


View and export this data going back to 2017. Start your Free Trial

What is BerGenBio ASA LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. BerGenBio ASA's long-term debt to total assests ratio for the quarter that ended in Dec. 2023 was 0.00.

BerGenBio ASA's long-term debt to total assets ratio declined from Dec. 2022 (0.00) to Dec. 2023 (0.00). It may suggest that BerGenBio ASA is progressively becoming less dependent on debt to grow their business.


BerGenBio ASA LT-Debt-to-Total-Asset Historical Data

The historical data trend for BerGenBio ASA's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BerGenBio ASA LT-Debt-to-Total-Asset Chart

BerGenBio ASA Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only - - - - -

BerGenBio ASA Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 0.01 - - -

BerGenBio ASA LT-Debt-to-Total-Asset Calculation

BerGenBio ASA's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )/Total Assets (A: Dec. 2023 )
=0/174.335
=0.00

BerGenBio ASA's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (Q: Dec. 2023 )=Long-Term Debt & Capital Lease Obligation (Q: Dec. 2023 )/Total Assets (Q: Dec. 2023 )
=0/174.335
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BerGenBio ASA  (OSTO:BGBIOO) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.


BerGenBio ASA LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of BerGenBio ASA's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


BerGenBio ASA (OSTO:BGBIOO) Business Description

Traded in Other Exchanges
Address
Mollendalsbakken 9, Bergen, NOR, 5009
BerGenBio ASA is a clinical stage oncology biotech company, which is engaged in developing therapeutics against novel drug targets that drive aggressive cancers. Its drug candidate bemcentinib (BGB324) is d is curently being developed in STK11 mutated NSCLC and severe respiratory infections including COVID-19. .

BerGenBio ASA (OSTO:BGBIOO) Headlines

No Headlines